We are developing the next generation of bio-therapeutics for the treatment of autoimmunity and cancer. Recent breakthroughs in the field of immunology and immuno-oncology have opened the way for a new wave of transformative treatments. Despite these clinical successes, the full potential of harnessing the immune system has not yet been realized. Abcuro’s mission is to develop a new class of immune modulatory bio-therapeutics for treating both autoimmunity and cancer. We leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Our intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue has uncovered new approaches to target key compartments of the immune system.